Casting Versus Flexible Intramedullary Nailing in Displaced Pediatric Forearm Shaft Fractures
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Dec 10, 2020
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to treat broken forearm bones in children aged 7 to 12 years old. The trial compares the traditional method of putting the arm in a cast after gently realigning the bones (called closed reduction and casting) to a newer method that uses flexible rods inserted into the bone (called flexible intramedullary nailing). Researchers want to find out if one method works better than the other in helping children heal from these fractures and avoid problems later on.
To be eligible for the trial, children must be between 7 and 12 years old and have a specific type of broken forearm where the bones are misaligned by more than 10 degrees. Children with more serious conditions, such as multiple fractures or infections, cannot participate. If a child joins the study, they will receive one of the two treatments and will be monitored to see how well their arm heals. This trial is currently recruiting participants, and it aims to improve the way we treat forearm fractures in children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 7 to12 year old children
- • Open distal radial physis
- • Both bone forearm shaft fractures (AO-pediatric classification: 22D/2.1-5.2)
- • More than 10 degrees of angulation
- • with or without less than 10mm of shortening
- Exclusion Criteria:
- • Patients with bilateral fractures
- • Gustilo-Anderson grade I-III open fracture
- • Neurovascular deficit
- • Compartment syndrome
- • Pathologic fracture
- • Patient not able to give a written informed consent
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuopio, , Finland
Oulu, , Finland
Tampere, , Finland
Turku, , Finland
Helsinki, , Finland
Patients applied
Trial Officials
Ilkka Helenius, MD
Study Director
Helsinki University Central Hospital
Petra Grahn, MD
Principal Investigator
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials